# Ken Herrmann

Source: https://nuclide.cc/people/ken-herrmann/  
Nuclide record `ken-herrmann` (Person). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Nuclear medicine leader who co-led VISION and runs one of the world's largest theranostics programmes.

## Summary

Ken Herrmann was a lead investigator of VISION and of the German multicentre 177Lu-PSMA-617 registry, and leads the Essen theranostics centre that has treated thousands of patients with PSMA and somatostatin receptor radioligands. He has chaired the EANM oncology committee, co-authored the Lancet Oncology series on theranostics, and leads trials of alpha emitters and new targets such as FAP.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: radioligand; nuclear-medicine; germany
- Role: Chair of Nuclear Medicine, University Hospital Essen
- Specialisms: Theranostics; PSMA radioligand therapy; Nuclear medicine; Radiopharmaceutical trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Herrmann%20K%5BAuthor%5D%20theranostics%20PSMA

## Connected records

- isotopes: [Lutetium-177](https://nuclide.cc/isotopes/lu-177/)
- indications: [Neuroendocrine tumours](https://nuclide.cc/indications/neuroendocrine/), [Prostate cancer](https://nuclide.cc/indications/prostate/)
- technologies: [FAPI PET](https://nuclide.cc/technologies/fapi-pet/), [PSMA PET](https://nuclide.cc/technologies/psma-pet/), [Radioligand therapy (beta emitters)](https://nuclide.cc/technologies/radioligand-therapy/)
- targets: [FAP](https://nuclide.cc/targets/fap/), [PSMA](https://nuclide.cc/targets/psma/)
- drugs: [Lutetium-177 dotatate](https://nuclide.cc/drugs/lutathera/), [Lutetium-177 vipivotide tetraxetan](https://nuclide.cc/drugs/pluvicto/)
- institutions: [European Association of Nuclear Medicine](https://nuclide.cc/institutions/eanm/), [West German Cancer Center (WTZ), University Hospital Essen](https://nuclide.cc/institutions/essen-wtz/)
- trials: [VISION](https://nuclide.cc/trials/vision/)
- key papers: [PSMAfore: 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor in taxane-naive mCRPC](https://nuclide.cc/key-papers/paper-psmafore-lancet-2024/), [Radiotheranostics: a roadmap for future development](https://nuclide.cc/key-papers/paper-herrmann-radiotheranostics-lancet-oncol-2020/), [VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer](https://nuclide.cc/key-papers/paper-vision-nejm-2021/)
- people: [Wolfgang P. Fendler](https://nuclide.cc/people/wolfgang-fendler/)
- roadmaps: [Dosimetry roadmap: MIRD schema → fixed dosing → personalised, image-based dose](https://nuclide.cc/roadmaps/dosimetry-roadmap/)

---
JSON: https://nuclide.cc/api/v1/entities/ken-herrmann.json